Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses

Authors

  • Khaled Ezzedine
  • Caroline Painchault
  • Melanie Brignone Pierre Fabre, 45 Place Abel Gance, FR-92100 Boulogne-Billancourt, France

DOI:

https://doi.org/10.2340/00015555-3690

Keywords:

actinic keratosis, systematic literature review, network meta-analysis, field-directed intervention

Abstract

A systematic literature review was conducted to identify and qualitatively assess randomized controlled trials in immunocompetent patients ≥ 18 years with head- region lesions of actinic keratoses who were treated with field-directed, lesion-directed and other therapies. Network meta-analysis was used to quantitatively evaluate field-directed therapies (5-fluorouracil formulations, diclofenac sodium, imiquimod, ingenol mebutate, 5-aminolevulinic acid or methyl aminolevulinate plus photodynamic therapy) using complete clearance or partial clearance of actinic keratoses lesions, and adverse event-related withdrawals as a proxy of acceptability. Of 2,863 references identified, 75 trials reported in 151 publications were included. In summary, comparative network meta-analysis evaluation showed that 5-fluorouracil formulations were the most efficacious interventions examined. 5-fluorouracil 4%, which was recently approved, showed a comparable efficacy profile to 5-fluorouracil 5%, and had satisfactory acceptability outcomes.

Downloads

Download data is not yet available.

References

Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165: 1101-1108.

DOI: https://doi.org/10.1111/j.1365-2133.2011.10387.x

de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol 2017; 176: 20-43.

DOI: https://doi.org/10.1111/bjd.15107

Traianou A, Ulrich M, Apalla Z, De Vries E, Bakirtzi K, Kalabalikis D, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol 2012; 167 Suppl 2: 36-42.

DOI: https://doi.org/10.1111/j.1365-2133.2012.11085.x

Stockfleth E, von Kiedrowski R, Dominicus R, Ryan J, Ellery A, Falques M, et al. Efficacy and safety of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther (Heidelb) 2017A; 7: 81-96.

DOI: https://doi.org/10.1007/s13555-016-0161-2

Dirschka T, Gupta G, Micali G, Stockfleth E, Basset-Seguin N, Del Marmol V, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat 2017; 28: 431-442.

DOI: https://doi.org/10.1080/09546634.2016.1254328

Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence- and Consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in Cooperation with the European Dermatology Forum - Short Version. J Eur Acad Dermatol Venereol 2015; 29: 2069-2079.

DOI: https://doi.org/10.1111/jdv.13180

Wolf JE, Jr., Rigel DS. Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis. Int J Dermatol 2013; 52: 1063-1070.

DOI: https://doi.org/10.1111/j.1365-4632.2012.05776.x

Goldenberg G. Treatment considerations in actinic keratosis. J Eur Acad Dermatol Venereol 2017; 31 Suppl 2: 12-16.

DOI: https://doi.org/10.1111/jdv.14152

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.

DOI: https://doi.org/10.1016/j.ijsu.2010.02.007

Critical Appraisal Skills Programme (CASP). CASP checklist: 11 questions to help you make sense of a randomised controlled trial. 2017. [cited 28 November 2019]. Available from: DOI: https://casp-uk.net/wp-content/uploads/2018/01/CASP-Randomised-Controlled-Trial-Checklist-2018.pdf.

Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013; 169: 250-259.

DOI: https://doi.org/10.1111/bjd.12343

Dias S, Welton NJ, Sutton AJ, Ades AE. NICE Decision Support Unit technical support documents. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2014.

Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 2002; 64: 583-639.

DOI: https://doi.org/10.1111/1467-9868.00353

Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.

DOI: https://doi.org/10.1016/S0895-4356(97)00049-8

Dohil MA. Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis. J Drugs Dermatol 2016; 15: 1218-1224.

Data on file. HD-FUP4LTS-050: an open-label, multi-center, uncontrolled, single-group assignment, long-term safety study of 4% 5-FU cream in subjects with actinic keratosis (who participated in the phase III studies). Pierre Fabre, France, 2008.

Hauschild A, Popp G, Stockfleth E, Meyer KG, Imberger D, Mohr P, et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol 2009; 18: 116-121.

DOI: https://doi.org/10.1111/j.1600-0625.2008.00770.x

Hauschild A, Stockfleth E, Popp G, Borrosch F, Bruning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009; 160: 1066-1074.

DOI: https://doi.org/10.1111/j.1365-2133.2009.09040.x

Akarsu S, Aktan S, Atahan A, Koc P, S. Ö. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. Clin Exp Dermatol 2011; 36: 479-484.

DOI: https://doi.org/10.1111/j.1365-2230.2010.03999.x

Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-141.

DOI: https://doi.org/10.1111/j.1365-2133.2007.07942.x

Augustin M, Tu JH, Knudsen KM, Erntoft S, Larsson T, Hanke CW. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol 2015; 72: 816-821.

DOI: https://doi.org/10.1016/j.jaad.2015.01.036

Data on file. HD-FUDR-045: A randomized, evaluator blinded, vehicle controlled, parallel group, dose ranging study of the safety and efficacy of 4% 5-FU cream versus its vehicle cream versus Efudex in the treatment of actinic keratosis. Pierre Fabre, France: 2005.

Data on file. HD-FUP3S-049: A randomized, double-blind, vehicle-controlled multi-center study of the safety and efficacy of 4% 5-FU cream versus its vehicle cream in the treatment of actinic keratosis. Pierre Fabre, France, 2007.

Dirschka T, Radny P, Dominicus R, Mensing H, Bruning H, Jenne L, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137-146.

DOI: https://doi.org/10.1111/j.1365-2133.2011.10613.x

Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14: 99-106.

DOI: https://doi.org/10.1080/09546630310012118

Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-268.

DOI: https://doi.org/10.1016/j.jaad.2007.01.047

Jorizzo J, Stewart D, Bucko A, Davis SA, Espy P, Hino P, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002; 70: 335-339.

Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol 2006; 5: 133-139.

Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157 Suppl 2: 34-40.

DOI: https://doi.org/10.1111/j.1365-2133.2007.08271.x

Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-721.

DOI: https://doi.org/10.1016/j.jaad.2003.12.010

Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther 2001; 23: 908-920.

DOI: https://doi.org/10.1016/S0149-2918(01)80078-3

Clinicaltrials.gov, NCT00828568. Bioequivalence Study of Two Imiquimod Cream 5%. [cited 1 December 2019]. Available from: DOI: https://clinicaltrials.gov/ct2/show/study/NCT00828568.

Ortonne JP, Gupta G, Ortonne N, Duteil L, Queille C, Mallefet P. Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol 2010; 19: 641-647.

DOI: https://doi.org/10.1111/j.1600-0625.2009.01047.x

Pariser D, Loss R, Jarratt M, Abramovits W, Spencer J, Geronemus R, et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59: 569-576.

DOI: https://doi.org/10.1016/j.jaad.2008.05.031

Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-232.

DOI: https://doi.org/10.1067/mjd.2003.49

Samorano LP, Torezan LA, Sanches JA. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol 2015; 29: 1822-1827.

DOI: https://doi.org/10.1111/jdv.13063

Sarbu I, Tampa M, Georgescu S. A randomized, double-blind, placebo-controlled, comparative study of the use of three topical products of different diclofenac concentrations in the treatment of actinic cheilitis. J Invest Dermatol 2012; 132: S66.

Serra-Guillén C, Nagore E, Hueso L, Traves V, Messeguer F, Sanmartín O, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012; 66: e131-137.

DOI: https://doi.org/10.1016/j.jaad.2011.11.933

Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head. J Am Acad Dermatol 2010; 62: AB105.

DOI: https://doi.org/10.1016/j.jaad.2009.11.416

Stockfleth E, Harwood CA, Serra-Guillen C, Larsson T, Osterdal ML, Skov T. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Br J Dermatol 2017B;178: 433-442.

DOI: https://doi.org/10.1111/bjd.16048

Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582-590.

DOI: https://doi.org/10.1016/j.jaad.2009.07.004

Szeimies RM, Atanasov P, Bissonnette R. Use of lesion response rate in actinic keratosis trials. Dermatol Ther (Heidelb) 2016; 6: 461-464.

DOI: https://doi.org/10.1007/s13555-016-0145-2

Szeimies RM, Matheson RT, Davis SA, Bhatia AC, Frambach Y, Klovekorn W, et al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg 2009; 35: 586-592.

DOI: https://doi.org/10.1111/j.1524-4725.2009.01096.x

Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krahn-Senftleben G, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163: 386-394.

DOI: https://doi.org/10.1111/j.1365-2133.2010.09873.x

Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144-147.

Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70: 22-29.

Zane C, Facchinetti E, Rossi MT, Specchia C, Calzavara-Pinton PG. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol 2014A; 170: 1143-1150.

DOI: https://doi.org/10.1111/bjd.12844

Data on file. HD-FUP3B-048: A randomized, evaluator blinded, vehicle-controlled multi-center study of the safety and efficacy of 4% 5-FU cream versus its vehicle cream versus efudex cream in the treatment of actinic keratosis. Pierre Fabre, France, 2007.

Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits A, van Pelt HPA, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 2019; 380: 935-946.

DOI: https://doi.org/10.1056/NEJMoa1811850

Ezzedine K, Painchault C, Brignone M. PNS6 Systematic literature review and qualitative analysis assessing efficacy safety of interventions in actinic keratosis. Value in Health 2019; 22: S763-S764.

DOI: https://doi.org/10.1016/j.jval.2019.09.1909

Published

2021-01-04

How to Cite

Ezzedine, K., Painchault, C., & Brignone, M. (2021). Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses. Acta Dermato-Venereologica, 101(1), adv00358. https://doi.org/10.2340/00015555-3690